Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines

References

• Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual report of the American association of poison control centers’ national poison data system (NPDS): 38th annual report. Clin Toxicol. 2021;59(12):1282–1501.
   PubMed Web of Science ®Google Scholar
• Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med. 2018;36(10):1817–1824.
   PubMed Web of Science ®Google Scholar
• St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. Crit Care Med. 2017;45(3):e306–e315.
   PubMedGoogle Scholar
• Page CB, Ryan NM, Isbister GK. The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity. Clin Toxicol. 2018;56(6):389–396.
   Web of Science ®Google Scholar
• Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol. 2011;49(4):277–283.
   Web of Science ®Google Scholar
• von Lewinski D, Bruns S, Walther S, et al. Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium. Circulation. 2005;111(20):2588–2595.
   PubMed Web of Science ®Google Scholar
• Cole JB, Stellpflug SJ, Ellsworth H, et al. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock. Clin Toxicol. 2013;51(4):201–207.
   Web of Science ®Google Scholar
• Lheureux PER, Zahir S, Gris M, et al. Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care. 2006;10(3):212.
   PubMed Web of Science ®Google Scholar
• Kline JA, Raymond RM, Leonova ED, et al. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34(2):289–298.
   PubMed Web of Science ®Google Scholar
• Reikerås O, Gunnes P, Sørlie D, et al. Metabolic effects of low and high doses of insulin during beta-receptor blockade in dogs. Clin Physiol. 1985;5(5):469–478.
   PubMedGoogle Scholar
• St-Onge M. Cardiovascular drug toxicity. Crit Care Clin. 2021;37(3):563–576.
   PubMed Web of Science ®Google Scholar
• Schoffstall JM, Spivey WH, Gambone LM, et al. Effects of calcium channel blocker overdose-induced toxicity in the conscious dog. Ann Emerg Med. 1991;20(10):1104–1108.
   PubMed Web of Science ®Google Scholar
• Engebretsen KM, Morgan MW, Stellpflug SJ, et al. Addition of phenylephrine to high-dose insulin in dihydropyridine overdose does not improve outcome. Clin Toxicol. 2010;48(8):806–812.
   Web of Science ®Google Scholar
• Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14(1):67–72.
   PubMedGoogle Scholar
• Deters M, Bergmann I, Enden G, et al. Calcium channel antagonist exposures reported to the Poisons Information Center Erfurt. Eur J Intern Med. 2011;22(6):616–620.
   PubMed Web of Science ®Google Scholar
• Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann Emerg Med. 2011;58(6):565–567.
   PubMed Web of Science ®Google Scholar
• Xu B, Xiao-hong L, Lin G, et al. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol. 2002;136(3):375–382.
   PubMed Web of Science ®Google Scholar
• Zhang X-P, Loke KE, Mital S, et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R + enantiomer of amlodipine. J Cardiovasc Pharmacol. 2002;39(2):208–214.
   PubMed Web of Science ®Google Scholar
• American Association of Poison Control Centers. National Poison Data System (NPDS): NPDS coding users’ manual version 4.1. Arlington (VA): American Association of Poison Control Systems; 2019.
   Google Scholar
• American Association of Poison Control Centers. National Poison Data System (NPDS): NPDS coding users’ manual version 4.3. Arlington (VA): American Association of Poison Control Systems; 2020.
   Google Scholar
• Warrick BJ, Tataru AP, Smolinske S. A systematic analysis of methylene blue for drug-induced shock. Clin Toxicol. 2016;54(7):547–555.
   Web of Science ®Google Scholar
• Chen A, Wong A. The role of angiotensin II in poisoning-induced shock-a review. J Med Toxicol. 2022;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Visscher MB, Müller EA. The influence of insulin upon the mammalian heart. J Physiol. 1927;62(4):341–348.
   PubMedGoogle Scholar
• Kline JA, Tomaszewski CA, Schroeder JD, et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993;267(2):744–750.
   PubMed Web of Science ®Google Scholar
• Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. 1995;23(7):1251–1263.
   PubMed Web of Science ®Google Scholar
• Kline JA, Leonova E, Williams TC, et al. Myocardial metabolism during graded intraportal verapamil infusion in awake dogs. J Cardiovasc Pharmacol. 1996;27(5):719–726.
   PubMed Web of Science ®Google Scholar
• Kline JA, Raymond RM, Schroeder JD, et al. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol. 1997;145(2):357–362.
   PubMed Web of Science ®Google Scholar
• Yuan TH, Kerns WP 2nd, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37(4):463–474.
   PubMed Web of Science ®Google Scholar
• Laes JR, Williams DM, Cole JB. Improvement in hemodynamics after methylene blue administration in drug-induced vasodilatory shock: a case report. J Med Toxicol. 2015;11(4):460–463.
   PubMed Web of Science ®Google Scholar
• Corcoran JN, Jacoby KJ, Olives TD, et al. Persistent hyperinsulinemia following high-dose insulin therapy: a case report. J Med Toxicol. 2020;16(4):465–469.
   PubMed Web of Science ®Google Scholar
• Smith SW, Ferguson KL, Hoffman RS, et al. Prolonged severe hypotension following combined amlodipine and valsartan ingestion. Clin Toxicol. 2008;46(5):470–474.
   Web of Science ®Google Scholar
• Azendour H, Belyamani L, Atmani M, et al. Severe amlodipine intoxication treated by hyperinsulinemia euglycemia therapy. J Emerg Med. 2010;38(1):33–35.
   PubMed Web of Science ®Google Scholar
• Koliastasis L, Lampadakis I, Milkas A, et al. Refractory shock from amlodipine overdose overcomed with hyperinsulinemia. Cardiovasc Toxicol. 2022;22(1):63–66.
   PubMed Web of Science ®Google Scholar
• Holger JS, Stellpflug SJ, Cole JB, et al. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol. 2011;49(7):653–658.
   Web of Science ®Google Scholar
• Espinoza TR, Bryant SM, Aks SE. Hyperinsulin therapy for calcium channel antagonist poisoning: a seven-year retrospective study. Am J Ther. 2013;20(1):29–31.
   PubMed Web of Science ®Google Scholar
• Lindeman E, Ålebring J, Johansson A, et al. The unknown known: non-cardiogenic pulmonary edema in amlodipine poisoning, a cohort study. Clin Toxicol. 2020;58(11):1042–1049.
   PubMed Web of Science ®Google Scholar
• Kline JA. Insulin for calcium channel toxicity. Ann Emerg Med. 2014;63(1):92–93.
   PubMed Web of Science ®Google Scholar
• Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest. 1994;94(6):2511–2515.
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94(3):1172–1179.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97(6):576–580.
   PubMed Web of Science ®Google Scholar
• Lenasi H, Kohlstedt K, Fichtlscherer B, et al. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res. 2003;59(4):844–853.
   PubMed Web of Science ®Google Scholar
• Batova S, DeWever J, Godfraind T, et al. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res. 2006;71(3):478–485.
   PubMed Web of Science ®Google Scholar
• LeRoy JM, Boley SP, Corcoran JN, et al. Effect of methylene blue on a porcine model of amlodipine toxicity. J Med Toxicol. 2020;16(4):398–404.
   PubMed Web of Science ®Google Scholar
• de Castro Brás LE, Baccanale CL, Eccleston L, et al. Efficacy of methylene blue in a murine model of amlodipine overdose. Am J Emerg Med. 2021;45:284–289.
   PubMed Web of Science ®Google Scholar
• Jang DH, Donovan S, Nelson LS, et al. Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock. Ann Emerg Med. 2015;65(4):410–415.
   PubMed Web of Science ®Google Scholar
• Nafea OE, Hassan HA. Comparative effectiveness of methylene blue versus intravenous lipid emulsion in a rodent model of amlodipine toxicity. Clin Toxicol. 2019;57(9):784–789.
   PubMed Web of Science ®Google Scholar
• Ferrari P, Giachino D, Weidmann P, et al. Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur J Clin Pharmacol. 1991;41(2):109–113.
   PubMed Web of Science ®Google Scholar
• de Courten M, Ferrari P, Schneider M, et al. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol. 1993;44(5):457–462.
   PubMed Web of Science ®Google Scholar
• Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med. 2004;43(7):561–565.
   PubMed Web of Science ®Google Scholar
• Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res. 2001;33(3):167–169.
   PubMed Web of Science ®Google Scholar
• Sueta D, Nakamura T, Dong Y-F, et al. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. Am J Hypertens. 2012;25(6):704–710.
   PubMed Web of Science ®Google Scholar
• Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071–2075.
   PubMed Web of Science ®Google Scholar
• Baron AD. Hemodynamic actions of insulin. Am J Physiol. 1994;267(2 Pt 1):E187–202.
   PubMedGoogle Scholar
• Cole JB, Corcoran JN, Engebretsen KM, et al. Use of a porcine model to evaluate the risks and benefits of vasopressors in propranolol poisoning. J Med Toxicol. 2020;16(2):212–221.
   PubMed Web of Science ®Google Scholar
• Holger JS, Engebretsen KM, Stellpflug SJ, et al. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med. 2014;63(1):91–92.
   PubMed Web of Science ®Google Scholar
• Schult RF, Nacca N, Grannell TL, et al. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. Am J Health Syst Pharm. 2022;79(7):547–555.
   PubMed Web of Science ®Google Scholar
• Stellpflug SJ, Harris CR, Engebretsen KM, et al. Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin. Clin Toxicol. 2010;48(3):227–229.
   Web of Science ®Google Scholar
• Levine M, Curry SC, Padilla-Jones A, Ruha A-M. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med. 2013;62(3):252–258.
   Google Scholar
• Skoog CA, Engebretsen KM. Are vasopressors useful in toxin-induced cardiogenic shock? Clin Toxicol. 2017;55(4):285–304.
   PubMed Web of Science ®Google Scholar
• Katzung KG, Leroy JM, Boley SP, et al. A randomized controlled study comparing high-dose insulin to vasopressors or combination therapy in a porcine model of refractory propranolol-induced cardiogenic shock. Clin Toxicol. 2019;57(11):1073–1079.
   PubMed Web of Science ®Google Scholar
• Cole JB, Arens AM. Cardiotoxic medication poisoning. Emerg Med Clin North Am. 2022;40(2):395–416.
   PubMed Web of Science ®Google Scholar
• Prosser JM, Smith SW, Rhim ES, et al. Inaccuracy of ECG interpretations reported to the poison center. Ann Emerg Med. 2011;57(2):122–127.
   PubMed Web of Science ®Google Scholar
• Lévy A, Bailey B, Letarte A, et al. Unproven ingestion: an unrecognized bias in toxicological case series. Clin Toxicol. 2007;45(8):946–949.
   Web of Science ®Google Scholar
• Huang J, Buckley NA, Isoardi KZ, et al. Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning. Clin Toxicol. 2021;59(6):464–471.
   PubMed Web of Science ®Google Scholar